 1. PSA progression defined by a minimum of two rising PSA levels with an interval of 1 week between each determination. Patients who received an anti-androgen must have progression documented by a minimum of two rising PSA levels with an interval of 1 week between each determination such that at least the second of these rises is 4 weeks since last flutamide, bicalutamide or nilutamide. 